GKOSHealthcare · Medical DevicesThe 14 Wall Street analysts covering Glaukos Corp. hold a median 12-month price target of $195 — +5.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Glaukos Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (98): Analysts have, on balance, been raising their forecasts.
Issuance (51): The company has been issuing shares or taking on financing, diluting existing holders.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GKOS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +5.7% from it.
Of the 20 most recent actions, 12 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | BTIG | Maintains | Buy | $164 → $193 |
| 30 July 2026 | Citigroup | Maintains | Buy | $175 → $188 |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | $168 → $195 |
| 30 July 2026 | Needham | Maintains | Buy | $150 → $201 |
| 30 July 2026 | Piper Sandler | Reiterates | Overweight | $165 → $195 |
| 30 July 2026 | Stifel | Maintains | Buy | $175 → $190 |
| 30 July 2026 | Truist Securities | Maintains | Buy | $180 → $215 |
| 30 July 2026 | UBS | Maintains | Neutral | $150 → $172 |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | $138 → $178 |
| 28 July 2026 | UBS | Assumes | Neutral | $150 |
| 17 July 2026 | Stifel | Maintains | Buy | $170 → $175 |
| 17 July 2026 | Stifel | Maintains | Buy | — |
| 16 July 2026 | Truist Securities | Maintains | Buy | $160 → $180 |
| 16 July 2026 | Truist Securities | Maintains | Buy | — |
| 8 July 2026 | Citigroup | Maintains | Buy | $162 → $175 |
| 8 July 2026 | Citigroup | Maintains | Buy | — |
| 6 July 2026 | HC Wainwright & Co. | Initiates | Buy | $168 |
| 6 July 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 1 July 2026 | Piper Sandler | Reiterates | Overweight | $165 |
| 1 July 2026 | Piper Sandler | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GKOS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 10% of US stocks
Cheaper than 7% of US stocks
Cheaper than 98% of US stocks
Higher than 86% of US stocks
Higher than 75% of US stocks
Higher than 92% of US stocks
Higher than 25% of US stocks
Higher than 13% of US stocks
Higher than 29% of US stocks
Higher than 31% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Glaukos Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Glaukos reported a narrower Q2 loss and a 50% revenue increase, driven by iDose TR and Epioxa growth. The company lifted its 2026 sales outlook, and shares rose 9.8%.
Why it matters — GKOS watchers would note the strong revenue growth and raised outlook as signs of commercial momentum for iDose TR and Epioxa.
Glaukos reported record second-quarter 2026 consolidated net sales of $185.6 million, a 50% year-over-year increase, driven by growth exceeding expectations in its U.S. glaucoma, international glaucoma and corneal health businesses.
Why it matters — The results indicate that Glaukos's core business segments are outperforming the company's own forecasts, which may inform expectations for future performance.
Zacks Investment Research reported that Glaukos (GKOS) released its Q2 2026 earnings, with the analysis focusing on how its revenue, EPS, and other key metrics compare to Wall Street estimates and the prior-year period.
Why it matters — A GKOS watcher would care because the quarter's revenue and earnings figures give a sense of how the business performed relative to analyst expectations and last year's results.
Glaukos Corporation held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha.
Why it matters — The earnings call transcript provides Glaukos investors and analysts with management's official commentary on the company's second-quarter financial results and business outlook.
Glaukos reported a second-quarter net loss of $0.14 per share, narrower than the Zacks Consensus Estimate of a $0.28 loss and improved from the $0.24 loss a year earlier. Revenue also exceeded analyst expectations.
Why it matters — The narrower-than-expected loss and revenue beat signal potential operating improvement, which investors tracking GKOS profitability trends would note.
The 14 Wall Street analysts covering Glaukos Corp. have a median 12-month price target of $195, with estimates ranging from $172 to $225. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Glaukos Corp., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Glaukos Corp. 90 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Glaukos Corp. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (98 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +5.7% from the last close, and Ticker Nerd's factor model ranks Glaukos Corp. 90 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Glaukos Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GKOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $172 to $225 over the next 12 months.
Glaukos Corp. returned +102.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Glaukos Corporation is a medical technology company dedicated to the development and commercialization of innovative products for the treatment of glaucoma, corneal disorders, and retinal diseases. Its primary function is to address the substantial unmet medical needs present in ophthalmic healthcare.
The most recent item we track (Zacks Investment Research, 30 July 2026): "Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up". Glaukos reported a narrower Q2 loss and a 50% revenue increase, driven by iDose TR and Epioxa growth. The company lifted its 2026 sales outlook, and shares rose 9.8%.
Glaukos Corporation is a medical technology company dedicated to the development and commercialization of innovative products for the treatment of glaucoma, corneal disorders, and retinal diseases. Its primary function is to address the substantial unmet medical needs present in ophthalmic healthcare. Glaukos is particularly recognized for pioneering novel micro-invasive glaucoma surgery (MIGS) devices, which are designed to reduce intraocular pressure in glaucoma patients through minimally invasive techniques. The company's product portfolio includes various implantable devices and surgical systems, offering alternatives to traditional invasive surgery and medication. Glaukos Corporation significantly impacts the healthcare industry, especially the ophthalmology sector, by providing solutions that improve patient outcomes and quality of life. Its innovations are crucial in the market, as glaucoma remains one of the leading causes of irreversible blindness globally. By focusing on clinically proven products and expanding its technological reach, Glaukos plays a transformative role in enhancing therapeutic standards and contributing to greater accessibility of advanced eye care treatments.
CEO Mr. Thomas William Burns · 1,094 employees · United States · https://www.glaukos.com